KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $268,000.

  • Arbutus Biopharma's Non-Current Assets fell 96.50% to $268,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $268,000, marking a year-over-year decrease of 96.50%. This contributed to the annual value of $4.4 million for FY2024, which is 64.51% down from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Non-Current Assets is $268,000, which was up 81.08% from $148,000 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Non-Current Assets ranged from a high of $64.2 million in Q1 2022 and a low of $148,000 during Q2 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $11.8 million (2024), whereas its average is $11.3 million.
  • Per our database at Business Quant, Arbutus Biopharma's Non-Current Assets spiked by 621.19% in 2022 and then plummeted by 98.75% in 2025.
  • Arbutus Biopharma's Non-Current Assets (Quarterly) stood at $43.8 million in 2021, then climbed by 1.04% to $44.3 million in 2022, then tumbled by 72.06% to $12.4 million in 2023, then crashed by 64.51% to $4.4 million in 2024, then plummeted by 96.50% to $268,000 in 2025.
  • Its Non-Current Assets stands at $268,000 for Q3 2025, versus $148,000 for Q2 2025 and $202,000 for Q1 2025.